L-Serine Reduces Reactive Oxygen Species Yield in Cisplatin Treated Zebrafish Utricles
Grade Level at Time of Presentation
Sophomore
Major
Biology
2nd Grade Level at Time of Presentation
Sophomore
2nd Student Major
Biology
Institution
Western Kentucky University
KY House District #
7
KY Senate District #
8
Faculty Advisor/ Mentor
Dr. Michael Smith; Mr. Jerry Munroe
Department
Dept. of Biology
Abstract
Cisplatin is a chemotherapy compound effective against a variety of cancers. However, it can act as an ototoxin and cause hearing loss by promoting reactive oxygen species (ROS) production in auditory tissues. The antioxidant amino acid, L-serine has been hypothesized to lower levels of cisplatin-mediated ROS. In this project, we investigated whether L-serine can reduce cisplatin-mediated ROS production in auditory tissue and potentially act as an otoprotectant during cisplatin chemotherapy. We used a zebrafish utricular tissue culture system and fluorescent ROS indicator dye to spectrophotometrically measure if L-serine could decrease reactive oxygen species levels in cisplatin-treated tissues. We found that cisplatin treatment increased ROS yield in the utricular tissue while L-serine treatment alone did not alter ROS levels. Interestingly, we also found that equimolar L-serine treatment with cisplatin restored ROS to control levels. These results could be due to L-serine acting as an ROS scavenger. However, it is possible that L-serine could chemically inactivate cisplatin in these tissues. Future experiments are needed to see if L-serine can act as an otoprotectant in auditory tissue without mitigating the effects of cisplatin in cancer cells.
L-Serine Reduces Reactive Oxygen Species Yield in Cisplatin Treated Zebrafish Utricles
Cisplatin is a chemotherapy compound effective against a variety of cancers. However, it can act as an ototoxin and cause hearing loss by promoting reactive oxygen species (ROS) production in auditory tissues. The antioxidant amino acid, L-serine has been hypothesized to lower levels of cisplatin-mediated ROS. In this project, we investigated whether L-serine can reduce cisplatin-mediated ROS production in auditory tissue and potentially act as an otoprotectant during cisplatin chemotherapy. We used a zebrafish utricular tissue culture system and fluorescent ROS indicator dye to spectrophotometrically measure if L-serine could decrease reactive oxygen species levels in cisplatin-treated tissues. We found that cisplatin treatment increased ROS yield in the utricular tissue while L-serine treatment alone did not alter ROS levels. Interestingly, we also found that equimolar L-serine treatment with cisplatin restored ROS to control levels. These results could be due to L-serine acting as an ROS scavenger. However, it is possible that L-serine could chemically inactivate cisplatin in these tissues. Future experiments are needed to see if L-serine can act as an otoprotectant in auditory tissue without mitigating the effects of cisplatin in cancer cells.